• Company
• Reimb for the petitioned ADC drug Enhertu unclear
• by Eo, Yun-Ho Aug 31, 2023 05:25am

• Policy
• NHIS may cover high-priced new drugs with refund-type RSA
• by Lee, Tak-Sun Aug 31, 2023 05:25am

• Opinion
• [Reporter’s View] M&A storm blows through industry
• by Lee, Seok-Jun Aug 30, 2023 05:32am

• Company
• Leclaza’s cumulative sales reach KRW 30 bil in 2 yrs
• by Chon, Seung-Hyun Aug 30, 2023 05:32am

• Company
• Sales of Taxol & Genexol rise together
• by Kim, Jin-Gu Aug 30, 2023 05:31am

• Company
• Perjeta and Herceptin combination drug, Phesgo
• by Eo, Yun-Ho Aug 30, 2023 05:31am

• Company
• Keytruda posts sales of KRW 183.8 bil in 1H...unrivaled lead
• by Chon, Seung-Hyun Aug 29, 2023 05:28am

• Policy
• Opdivo reimb as first-line therapy in gastric cancer in KOR
• by Lee, Tak-Sun Aug 29, 2023 05:28am

• Policy
• Hyundai Pharm's Hypejil 3mg
• by Lee, Tak-Sun Aug 29, 2023 05:28am

• Company
• The synergy between technology and sales force
• by Chon, Seung-Hyun Aug 29, 2023 05:28am